MR Guided Focused Ultrasound (FUS) for the Treatment of Trigeminal Neuralgia

Trigeminal Neuralgia Clinical Trial

Official title:

Phase 1 Clinical Trial for MR Guided Focused Ultrasound (FUS) Thalamotomy of Central Lateral Thalamic Nucleus for the Treatment of Medication-refractory Trigeminal Neuralgia

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04579692
• Other study ID #: HP-00092927
• Status: Recruiting
• Phase: N/A
• Start date: February 20, 2021
• Est. completion date: June 15, 2025

Study information

• Verified date: February 2024
• Source: University of Maryland, Baltimore
• Contact: Dheeraj Gandhi, MD
• Phone: (248)-497-8856
• Email: dgandhi[@]umm.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess the safety and effectiveness of MRI-guided focused ultrasound (MRgFUS) for treating Trigeminal Neuralgia. Trigeminal Neuralgia (pain) is a type of pain involving the face that can be disabling to those it affects.

Description:

The purpose of this study is to assess the safety and effectiveness of MRI-guided focused ultrasound (MRgFUS) for treating Trigeminal Neuralgia. Trigeminal Neuralgia (pain) is a type of pain involving the face that can be disabling to those it affects.

Usually, people with trigeminal pain receive medicines to control the pain. However, these medications may not give adequate pain relief. They may have unwanted side effects. In many patients with Trigeminal Neuralgia, a blood vessel compressing the nerve could be responsible for this condition. In such patients, surgery (also called micro-vascular decompression) is considered to be the best option if the medications do not control the pain. However, not all patients are good candidates for surgical correction and some patients may have recurrence of pain following surgical correction.

When surgery is not possible or recommended, other procedures are also available to patients. Such procedures usually result in selective damage to the nerve pain fibers in the Trigeminal nerve. Examples of these treatments include injection of materials such as Glycerol into the nerve, compression of the nerve with a balloon or selective radiation treatment of the nerve (stereotactic Radiosurgery). These treatments may not always improve the patient's pain or may only relieve the pain for a short duration of time.

These treatments may also result in damage to the nerve fibers that carry sensation from the face.

Our study will assess a new device for treating patients who have disabling pain that has not responded to medications or medications along with surgery. The device we will assess is called the ExAblate Transcranial focused ultrasound system. In this study, we will use this device to send ultrasound waves through the skull to precisely target and treat a tiny area of the brain called central lateral nucleus.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 10
• Est. completion date: June 15, 2025
• Est. primary completion date: June 15, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 21 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Clinical Diagnosis of Classical or Idiopathic TN refractory to medical therapy

2. Age greater than 21 and less than 75 years

3. Subjects who are able and willing to give consent and able to attend all study visits

4. Documented chronic, severe pain for more than 6 months duration

5. Failure to respond to the usual therapeutic regimen considered to be standard of care for Trigeminal Neuralgia. The patient should have failed a trial of at least two classes of therapeutic agents, including an anticonvulsant agent

6. Patient with Trigeminal Neuralagia who has either failed a prior surgical approach considered to be standard of care for TN (Micro-vascular decompression, radiofrequency, stereotactic, Radiosurgery or glycerol) or is not considered to be an acceptable candidate for one of those alternative options (due to anesthesia risk, medical comorbidities or Patient refusal despite counseling).

7. Central lateral thalamotomy is feasible based on evaluation of imaging studies

8. Patient able to communicate sensations during the Exablate TcMRgFUS treatment

9. Two members of the medical team have agreed upon inclusion and exclusion criteria.

Exclusion Criteria:

• Patient with contra-indications to MRI such as severe claustrophobia and metallic implants incompatible with MRI.

1. Severe psychiatric disorder such as uncontrolled depression, bipolar disorder, prior attempt at suicide or suicide ideation in preceding 12 months

2. Life expectancy less than 12 months

3. Anticoagulant or antiplatelet medications as well as underlying coagulopathy

4. Prior or currently implanted thalamic DBS

5. Pregnant ladies or women of childbearing age who are sexually active and not using contraception

6. Inability to provide informed consent, for example due to underlying cognitive impairment or aphasia

7. Presence of intracranial mass or an acute intracranial abnormality

8. Subjects with unstable cardiac status such as Unstable angina pectoris, documented myocardial infarction within 6 months of protocol entry and ejection fraction less than 40

9. Subjects exhibiting any behavior(s) consistent with ethanol or substance abuse as defined by the criteria outlined in the DSM-IV.

10. Severe hypertension (diastolic BP > 100 on medication or persistently elevated SBP>140 mmHg despite adequate antihypertensive medications)

11. History of immunocompromise including those who are HIV positive.

12. History of intracranial hemorrhage, traumatic brain injury or thalamic stroke.

13. Cerebrovascular disease (multiple CVA or CVA within 6 months)

14. Subjects with life-threatening systemic disease that include and not limited to the following will be excluded from the study participation: HIV, Liver Failure, blood dyscrasias, etc.

15. Subjects with a history of seizures within the past year

16. Individuals who are not able or willing to tolerate the required prolonged stationary supine position during treatment (can be up to 4 hours of total table time.)

17. Are participating or have participated in another clinical trial in the last 30 days

18. Skull Density Ratio (SDR) less than 0.4 ± 0.05

19. History of multiple sclerosis.

Related Conditions & MeSH terms

• Neuralgia
• Trigeminal Neuralgia

Intervention

Device:
• ExAblate Transcranial treatment
Patients' head will be placed in ExAblate device to hold it still for the treatment. The ExAblate Transcranial helmet will be placed on their head. The investigators will measure the study participant's heart, blood pressure, temperature, and breathing rate before the treatment begins. MRI scans will be taken to make sure the ultrasound waves will be aimed exactly within the target. A series of MR images will be taken to identify the target area, and plan the study treatment. The study investigators will decide on the area of participant's brain that will be treated. The ExAblate Transcranial system will compute a plan to cover the treatment area. This area is gradually heated while monitoring the patient's responses and neurologic examination.

Locations

Country	Name	City	State
United States	University of Maryland Medical Center	Baltimore	Maryland

Sponsors (3)

Lead Sponsor	Collaborator
University of Maryland, Baltimore	Focused Ultrasound Foundation, InSightec

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of Treatment related adverse events	Procedure related or device related adverse events will be reported, from the treatment day through the 6-month follow-up period.	All events will be reported up to 6 months from treatment
Secondary	Change in pain intensity	Efficacy of ExAblate TcMRgFUS for Thalamotomy will be evaluated using Barrow Neurological Institute (BNI) pain intensity score.	6 months
Secondary	Change in pain intensity	Efficacy of ExAblate TcMRgFUS for Thalamotomy will be evaluated using Brief Pain Inventory-Facial.	6 months
Secondary	Change in pain intensity	Efficacy of ExAblate TcMRgFUS for Thalamotomy will be evaluated using Pain Numeric rating scale (NRS).	6 months
Secondary	Change in patient's perception of the effect of the procedure	Patient Global impression of change (PGIC): The effect of the procedure on patient perceived impact of pain related symptoms, emotions and quality of life will be measured using PGIC scale.	6 months